INHIBITOR: Retrospective Study Of Patients With Renal Cell Carcinoma And Mantle Cell Lymphoma Treated With Temsirolimus
N/A
18 Years
N/A
18 Years
N/A
Open (Enrolling)
Both
Carcinoma, Renal Cell, Lymphoma, Mantle-Cell
Both
Carcinoma, Renal Cell, Lymphoma, Mantle-Cell
Trial Information
INHIBITOR: Retrospective Study Of Patients With Renal Cell Carcinoma And Mantle Cell Lymphoma Treated With Temsirolimus
There is not sampling method
Inclusion Criteria:
Patients with Renal Cell Carcinoma or Mantle Cell Lymphoma that have been treated with
Temsirolimus as per clinical practice.
Exclusion Criteria:
Patients that do not have a minimum (pre-specified) of data in their clinical record.
Type of Study:
Observational
Study Design:
Observational Model: Case-Only, Time Perspective: Retrospective
Outcome Measure:
The principal objective of the study is to evaluate the efficacy and safety of temsirolimus use in patients with Renal Cell Carcinoma and Mantle Cell Lymphoma.
Outcome Time Frame:
1 year
Safety Issue:
Yes
Principal Investigator
Pfizer CT.gov Call Center
Investigator Role:
Study Director
Investigator Affiliation:
Pfizer
Authority:
Spain: Comité Ético de Investigación Clínica
Study ID:
B1771017
NCT ID:
NCT01367457
Start Date:
May 2011
Completion Date:
December 2013
Related Keywords:
- Carcinoma, Renal Cell
- Lymphoma, Mantle-cell
- Carcinoma
- Carcinoma, Renal Cell
- Lymphoma
- Lymphoma, Mantle-Cell
Name | Location |
|---|
